Health Condition 1: - Health Condition 2: D259- Leiomyoma of uterus, unspecified
Conditions
Interventions
Intervention1: Atorvastatin with Mifepristone vs Mifepristone: Two groups will be assigned, Group A and Group M.Group A will be given Tab Atorvastatin 20mg with Tab Mifepristone 25mg PER ORAL daily fo
Sponsors
Dr Riya Goyal
Eligibility
Inclusion criteria
Inclusion criteria: Patients in reproductive and perimenopausal age group with uterine fibroid having symptom.patients giving written informed consent.Patients who donot want surgery.
Exclusion criteria
Exclusion criteria: Patients with severe presentation of fibroid such as severe intauterine bleeding or severe dysmenorrhea.Associated uterine and adnexal pathology like ovarian,cervical or uterine malignancy and associated medical morbidity like presence of liver disease,renal disease,myopathy,pancreatitis,hypersensitivity reaction and diabetes mellitus.patient necessitating early surgical intervention for uterine leiomyoma.Hormonal contraception or any hormonal therapy in the previous three months.Post menopausal women.Not willing to participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the effect of atorvastatin with mifepristone and mifepristone alone on the size of leiomyoma,endometrial thickness and pattern,dysmenorrhea,heavy menstrual bleeding and quality of lifeTimepoint: The following parameters are recorded at the start of the study and at the completion of three months. USG(TVS/WA) VAS PBAC QOL | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the effectiveness of Atorvastatin with Mifepristone and mifepristone alone in medical management of fibroidTimepoint: The following parameters are recorded at the start of the study and at the completion of three months. USG(TVS/WA) VAS PBAC QOL | — |
Countries
India
Contacts
Public ContactDr Riya Goyal
Teerthanker Mahaveer Medical college and Research Centre, Moradabad
Outcome results
None listed